{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:09:32Z","timestamp":1768694972882,"version":"3.49.0"},"reference-count":119,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Knowledge of epidemiology, genetic etiopathogenesis, diagnostic criteria, and management of familial hypercholesterolemia have increased in the last two decades. Several population studies have shown that familial hypercholesterolemia is more frequent than previously thought, making this entity the most common metabolic disease with monogenic inheritence in the world. Identification of causal heterozygous pathogenic variants in LDLR, APOB, and PCSK9 genes have increased diagnostic accuracy of classical criteria (extreme hypercholesterolemia, personal \/ family history of premature coronary artery disease or other cardiovascular disease). Genetic screening has been recently introduced in many European countries to detect patients with familial hypercholesterolemia, mainly affected pediatric subjects, asymptomatic or those at the beggining of their disease, with the purpose of increasing surveillance and avoiding complications such as cardiovascular diseases. Cholesterol-lowering drugs should be started as soon as the diagnosis is made. Various combinations between drugs can be used when the goal is not achieved. New therapies, including small interference ribonucleic acids (siRNA) are being tested in different clinical trials.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1871530321666210208212148","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T06:16:51Z","timestamp":1612937811000},"page":"198-211","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Familial Hypercholesterolemia: Update and Review"],"prefix":"10.2174","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6274-6041","authenticated-orcid":true,"given":"Oscar Francisco","family":"Chac\u00f3n-Camacho","sequence":"first","affiliation":[{"name":"Deparment of Genetics, Institute of Ophthalmology \u201cConde de Valenciana, Mexico City, Mexico | Carrera de M\u00e9dico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Tlalnepantla, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glustein","family":"Pozo-Molina","sequence":"additional","affiliation":[{"name":"Carrera de M\u00e9dico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Tlalnepantla, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia Fabiola","family":"M\u00e9ndez-Catal\u00e1","sequence":"additional","affiliation":[{"name":"Carrera de M\u00e9dico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Tlalnepantla, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Reyes-Reali","sequence":"additional","affiliation":[{"name":"Carrera de M\u00e9dico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Tlalnepantla, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"M\u00e9ndez-Cruz","sequence":"additional","affiliation":[{"name":"Carrera de M\u00e9dico Cirujano, Facultad de Estudios Superiores Iztacala, Universidad Nacional Aut\u00f3noma de M\u00e9xico, Tlalnepantla, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Zenteno","sequence":"additional","affiliation":[{"name":"Deparment of Genetics, Institute of Ophthalmology \u201cConde de Valenciana, Mexico City, Mexico | Biochemistry Department, Faculty Medicine, National Autonomous University of Mexico, Mexico City, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.pathol.2018.10.014","volume":"51","author":"Berberich A.J.","year":"2019","unstructured":"Berberich A.J.; Hegele R.A.; The role of genetic testing in dyslipidaemia. Pathology 2019,51(2),184-192","journal-title":"Pathology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MOL.0000000000000388","volume":"28","author":"Hopkins P.N.","year":"2017","unstructured":"Hopkins P.N.; Genotype-guided diagnosis in familial hypercholesterolemia: population burden and cascade screening. Curr Opin Lipidol 2017,28(2),136-143","journal-title":"Curr Opin Lipidol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2014.12.036","volume":"239","author":"Bell D.A.","year":"2015","unstructured":"Bell D.A.; Pang J.; Burrows S.; Bates T.R.; van Bockxmeer F.M.; Hooper A.J.; O\u2019Leary P.; Burnett J.R.; Watts G.F.; Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. Atherosclerosis 2015,239(1),93-100","journal-title":"Atherosclerosis"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.001","volume":"22","year":"2016","unstructured":"EAS Familial Hypercholesterlaemia studies collaboration; Vellejo-Vaz, A.J.; Akman, A.; Seshasai S.R.K.; Cole, D.; Watts, G.F.; Hovingh, G.K.; Kastelein J.J.P.; Mata, P.; Raal, F.J.; Santos, R.D.; Soran, H.; Freiberger, T.; Abifadel, M.; Aguilar-Salinas, C.A.; Alnouri, F.; Alonso, R.; Al-Rasadi, K.; Banach, M.; Bogsrud, M.P.; Bourbon, M.; Bruckert, E.; Car, J.; Ceska, R.; Corral, P.; Descamps, O.; Dieplinger, H.; Do, C.T.; Durst, R.; Ezhov, M.V.; Fras, Z.; Gaita, D.; Gaspar, I.M.; Genest, J.; Harada-Shiba, G.; Jiang, L; Kayikcioglu, M.; Lam, C.S.P.; Latkovskis, G.; Laufs, U.; Liberopoulos, E.; Lin, J.; Lin, N.; Maher, V.; Majano, N.; Marais, A.D.; M&#xE4;rz, W.; Mirrakhimov, E.; Miserez A.R.; Mitchenko, O.; Nawawi, H.; Lennart, N.; Nordestgaard, B.G.; Paragh, G.; Petrulioniene, Z.; Pojskic, B.; Reiner, Z.; Sahebkar, A.; Santos, L.E.; Schunkert, H.; Shehab, A.;Slimane, M.N.; Stoll, M.; Su, T.; Susekov, A.; Tilney, M.; Tomlinson, B.; Tselepis, A.D.; Vohnout, B.; Wid&#xE9;n, E.; Yamashita, S.; Catapano, A.L.; Ray, K.K. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS familial hypercholesterlaemia studies collaboration. Atheroscler Suppl 2016,22,1-32","journal-title":"Atheroscler Suppl"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jacl.2015.12.019","volume":"10","author":"Andersen R.","year":"2016","unstructured":"Andersen R.; Andersen L.; Examining barriers to cascade screening for familial hypercholesterolemia in the United States. J Clin Lipidol 2016,10(2),225-227","journal-title":"J Clin Lipidol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1001\/jama.2016.6176","volume":"316","author":"Lozano P.","year":"2016","unstructured":"Lozano P.; Henrikson N.B.; Dunn J.; Morrison C.C.; Nguyen M.; Blasi P.R.; Anderson M.L.; Whitlock E.P.; Lipid sreening in childhood and adolescence for detection of familial hypercholesteroleaemia: evidence report and systematic review for the US preventive services task force. JAMA 2016,316(6),645-655","journal-title":"JAMA"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2016.08.018","volume":"253","author":"Catapano A.L.","year":"2016","unstructured":"Catapano A.L.; Graham G.; De Backer G.; Wiklund O.; Chapman J.; Drexel H.; Hoes A.W.; Jennings C.S.; Landmesser U.; Pedersen T.R.; Reiner Z.; Riccardi G.; Taskinen M-R.; Tokgozoglu L.; Verschuren W.M.M.; Vlachopoulos C.; Wood D.A.; Zamorano J.L.; ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of atherosclerosis of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention","journal-title":"Atherosclerosis"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1001\/jama.262.15.2092c","volume":"262","author":"Erkelens D.W.","year":"1989","unstructured":"Erkelens D.W.; Sherwood L.M.; Familial hypercholesterolemia, tendinous xanthomas, and Frans Hals. JAMA 1989,262(15),2092","journal-title":"JAMA"},{"key":"ref=9","first-page":"505","volume":"6","author":"Dequeker J.","year":"2004","unstructured":"Dequeker J.; Muls E.; Leenders K.; Xanthelasma and lipoma in Leonardo da Vinci\u2019s Mona Lisa. Isr Med Assoc J 2004,6(8),505-506","journal-title":"Isr Med Assoc J"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2174\/157340308783565401","volume":"4","author":"Ose L.","year":"2008","unstructured":"Ose L.; The real code of leonardo da vinci. Curr Cardiol Rev 2008,4(1),60-62","journal-title":"Curr Cardiol Rev"},{"key":"ref=11","first-page":"242","volume":"24","author":"Fagge C.H.","year":"1873","unstructured":"Fagge C.H.; Xanthomatous diseases of the skin. Trans Pathol Soc 1873,24,242-250","journal-title":"Trans Pathol Soc"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.0954-6820.1938.tb19279.x","volume":"89","author":"Muller C.","year":"1938","unstructured":"Muller C.; Xanthoma hypercholesterolaemia, angina pectoris. Acta Med Scand 1938,89,75-84","journal-title":"Acta Med Scand"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.7326\/0003-4819-29-4-671","volume":"29","author":"Wilkinson C.F.","year":"1948","unstructured":"Wilkinson C.F.; Hand E.A.; Fliegelman M.T.; Essential familial hypercholesterolemia. Ann Intern Med 1948,29(4),671-686","journal-title":"Ann Intern Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/0002-9343(64)90196-2","volume":"37","author":"Khachadurian A.K.","year":"1964","unstructured":"Khachadurian A.K.; The inheritance of essential familial hypercholesterolaemia. Am J Med 1964,37,402-407","journal-title":"Am J Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1073\/pnas.70.10.2804","volume":"70","author":"Goldstein J.L.","year":"1973","unstructured":"Goldstein J.L.; Brown M.S.; Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol. Proc Natl Acad Sci USA 1973,70(10),2804-2808","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1126\/science.185.4145.61","volume":"185","author":"Brown M.S.","year":"1974","unstructured":"Brown M.S.; Goldstein J.L.; Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science 1974,185(4145),61-63","journal-title":"Science"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.7164\/antibiotics.29.1346","volume":"29","author":"Endo A.","year":"1976","unstructured":"Endo A.; Kuroda M.; Tsujita Y.; ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 1976,29(12),1346-1348","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=18","first-page":"2996","volume":"36","author":"Kastelein J.J.","year":"2015","unstructured":"Kastelein J.J.; Ginsberg H.N.; Langslet G.; Hovingh G.H.; Ceska R.; Dufour R.; Blom R.; Civeira F.; Krempf M.; Lorenzato C.; Zhao J.; Pordy R.; Baccara,-Dinet, M.T; Gipe, D.A.; Geiger, M.J., Farnier, M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia. Eur Heart J 2015,36(43),2996-3003","journal-title":"Eur Heart J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"Sabatine M.S.","year":"2017","unstructured":"Sabatine M.S.; Giugliano R.P.; Keech A.C.; Honarpour N.; Wiviott S.D.; Murphy S.A.; Kuder J.F.; Wang H.; Liu T.; Wasserman S.M.; Sever P.S.; Pedersen T.R.; Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017,376(18),1713-1722","journal-title":"N Engl J Med"},{"key":"ref=20","first-page":"2863","volume":"Vol. II","author":"Golstein J.L.","year":"2001","unstructured":"Golstein J.L.; Hobbs H.H.; Brown M.S.; The metabolic and molecular bases of inherited disease 2001,Vol. II,2863-2913","journal-title":"The metabolic and molecular bases of inherited disease"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1210\/jc.2012-1563","volume":"97","author":"Benn M.","year":"2012","unstructured":"Benn M.; Watts G.F.; Tybjaerg-Hansen A.; Nordestgaard B.G.; Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012,97(11),3956-3964","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.ijcard.2014.04.165","volume":"174","author":"Shi Z.","year":"2014","unstructured":"Shi Z.; Yuan B.; Zhao D.; Taylor A.W.; Lin J.; Watts G.F.; Familial hypercholesterolemia in China: prevalence and evidence of underdetection and undertreatment in a community population. Int J Cardiol 2014,174(3),834-836","journal-title":"Int J Cardiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ijcard.2015.03.027","volume":"185","author":"Watts G.F.","year":"2015","unstructured":"Watts G.F.; Shaw J.E.; Pang J.; Magliano D.J.; Jennings G.L.R.; Carrington M.J.; Prevalence and treatment of familial hypercholesterolaemia in Australian communities. Int J Cardiol 2015,185,69-71","journal-title":"Int J Cardiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/eurheartj\/ehu058","volume":"36","author":"Sjouke B.","year":"2015","unstructured":"Sjouke B.; Kusters D.M.; Kindt I.; Besseling J.; Defesche J.C.; Sijbrands E.J.; Roeters van Lennep J.E.; Stalenhoef A.F.; Wiegman A.; de Graaf J.; Fouchier S.W.; Kastelein J.J.; Hovingh G.K.; Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015,36(9),560-565","journal-title":"Eur Heart J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","volume":"37","author":"Benn M.","year":"2016","unstructured":"Benn M.; Watts G.F.; Tybj&#xE6;rg-Hansen A.; Nordestgaard B.G.; Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217. Eur Heart J 2016,37(17),1384-1394","journal-title":"Eur Heart J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"Nordestgaard B.G.","year":"2013","unstructured":"Nordestgaard B.G.; Chapman M.J.; Humphries S.E.; Ginsberg H.N.; Masana L.; Descamps O.S.; Wiklund O.; Hegele R.A.; Raal F.J.; Defesche J.C.; Wiegman A.; Santos R.D.; Watts G.F.; Parhofer K.G.; Hovingh G.K.; Kovanen P.T.; Boileau C.; Averna M.; Bor&#xE9;n J.; Bruckert E.; Catapano A.L.; Kuivenhoven J.A.; Pajukanta P.; Ray K.; Stalenhoef A.F.H.; Stroes E.; Taskinen M.R.; Tybj&#xE6;rg-Hansen A.; Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J European Atherosclerosis Society Consensus Panel2013,34(45),3478-90a","journal-title":"Eur Heart J"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jacl.2015.06.015","volume":"9","author":"Miller P.E.","year":"2015","unstructured":"Miller P.E.; Martin S.S.; Toth P.P.; Santos R.D.; Blaha M.J.; Nasir K.; Virani S.S.; Post W.S.; Blumenthal R.S.; Jones S.R.; Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). J Clin Lipidol 2015,9(5),676-683","journal-title":"J Clin Lipidol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jacl.2014.08.009","volume":"9","author":"Muntoni S.","year":"2015","unstructured":"Muntoni S.; Pisciotta L.; Muntoni S.; Bertolini S.; Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH). J Clin Lipidol 2015,9(1),103-106","journal-title":"J Clin Lipidol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"e016461","DOI":"10.1136\/bmjopen-2017-016461","volume":"7","author":"Akioyamen L.E.","year":"2017","unstructured":"Akioyamen L.E.; Genest J.; Shan S.D.; Reel R.L.; Albaum J.M.; Chu A.; Tu J.V.; Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open 2017,7(9),e016461","journal-title":"BMJ Open"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","volume":"241","author":"De Backer G.","year":"2015","unstructured":"De Backer G.; Besseling J.; Chapman J.; Hoving G.K.; Kastelein J.J.P.; Kotseva K.; Ray K.; Reiner Z.; Wood D.; De Bacquer D.; EUROASPIRE Investigators. Prevalence and management of familial hypercholesterolaemia in coronary patients an analysis of EUROASPIRE IV, a study of the European Society od Cardiology. Atherosclerosis 2015,241(1),169-175","journal-title":"Atherosclerosis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1093\/eurheartj\/ehx136","volume":"38","author":"Nordestgaard B.G.","year":"2017","unstructured":"Nordestgaard B.G.; Benn M.; Genetic testing for familial hypercholesterolaemia is essential in individuals with high LDL cholesterol: who does it in the world? Eur Heart J 2017,38(20),1580-1583","journal-title":"Eur Heart J"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrg2481","volume":"10","author":"Hegele R.A.","year":"2009","unstructured":"Hegele R.A.; Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009,10(2),109-121","journal-title":"Nat Rev Genet"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","volume":"29","author":"Goldstein J.L.","year":"2009","unstructured":"Goldstein J.L.; Brown M.S.; The LDL receptor. Arterioscler Thromb Vasc Biol 2009,29(4),431-438","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1126\/science.3513311","volume":"232","author":"Brown M.S.","year":"1986","unstructured":"Brown M.S.; Goldstein J.L.; A receptor-mediated pathway for cholesterol homeostasis. Science 1986,232(4746),34-47","journal-title":"Science"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1210\/jc.2015-3874","volume":"101","author":"Cenarro A.","year":"2016","unstructured":"Cenarro A.; Etxebarria A.; de Castro-Or&#xF3;s I.; Stef M.; Bea A.M.; Palacios L.; Mateo-Gallego R.; Benito-Vicente A.; Ostolaza H.; Tejedor T.; Mart&#xED;n C.; Civeira F.; The p. Leu167del mutation in APOE gene causes autosomal dominant hypercholesterolemia by down-regulation of LDL receptor expression in hepatocytes. J Clin Endocrinol Metab 2016,101(5),2113-2121","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/CIRCRESAHA.115.304660","volume":"115","author":"Fouchier S.W.","year":"2014","unstructured":"Fouchier S.W.; Dallinga-Thie G.M.; Meijers J.C.; Zelcer N.; Kastelein J.J.; Defesche J.C.; Hovingh G.K.; Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res 2014,115(6),552-555","journal-title":"Circ Res"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.atherosclerosis.2014.04.003","volume":"235","author":"Reiner &#x17D;.","year":"2014","unstructured":"Reiner &#x17D;.; Guardamagna O.; Nair D.; Soran H.; Hovingh K.; Bertolini S.; Jones S.; \u0106ori\u0107 M.; Calandra S.; Hamilton J.; Eagleton T.; Ros E.; Ros E.; Lysosomal acid lipase deficiency--an under-recognized cause of dyslipidaemia and liver dysfunction. Atherosclerosis 2014,235(1),21-30","journal-title":"Atherosclerosis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1093\/hmg\/ddq352","volume":"19","author":"Rios J.","year":"2010","unstructured":"Rios J.; Stein E.; Shendure J.; Hobbs H.H.; Cohen J.C.; Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum Mol Genet 2010,19(22),4313-4318","journal-title":"Hum Mol Genet"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10408363.2011.565585","volume":"48","author":"Liyanage K.E.","year":"2011","unstructured":"Liyanage K.E.; Burnett J.R.; Hooper A.J.; van Bockxmeer F.M.; Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Crit Rev Clin Lab Sci 2011,48(1),1-18","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/humu.1380010602","volume":"1","author":"Hobbs H.H.","year":"1992","unstructured":"Hobbs H.H.; Brown M.S.; Goldstein J.L.; Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992,1(6),445-466","journal-title":"Hum Mutat"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/MOL.0000000000000404","volume":"28","author":"Bourbon M.","year":"2017","unstructured":"Bourbon M.; Alves A.C.; Sijbrands E.J.; Low-density lipoprotein receptor mutational analysis in diagnosis of familial hypercholesterolemia. Curr Opin Lipidol 2017,28(2),120-129","journal-title":"Curr Opin Lipidol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1469-1809.2012.00724.x","volume":"76","author":"Usifo E.","year":"2012","unstructured":"Usifo E.; Leigh S.E.A.; Whittall R.A.; Lench N.; Taylor A.; Yeats C.; Orengo C.A.; Martin A.C.R.; Celli J.; Humphries S.E.; Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment. Ann Hum Genet 2012,76(5),387-401","journal-title":"Ann Hum Genet"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1194\/jlr.D400030-JLR200","volume":"46","author":"Wang J.","year":"2005","unstructured":"Wang J.; Ban M.R.; Hegele R.A.; Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. J Lipid Res 2005,46(2),366-372","journal-title":"J Lipid Res"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/MOL.0000000000000073","volume":"25","author":"Santos R.D.","year":"2014","unstructured":"Santos R.D.; Maranhao R.C.; What is new in familial hypercholesterolemia? Curr Opin Lipidol 2014,25(3),183-188","journal-title":"Curr Opin Lipidol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jacl.2016.09.009","volume":"10","author":"Andersen L.H.","year":"2016","unstructured":"Andersen L.H.; Miserez A.R.; Ahmad Z.; Andersen R.L.; Familial defective apolipoprotein B-100: A&#xA0;review. J Clin Lipidol 2016,10(6),1297-1302","journal-title":"J Clin Lipidol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"12918","DOI":"10.1016\/S0021-9258(18)69248-8","volume":"261","author":"Chen S.H.","year":"1986","unstructured":"Chen S.H.; Yang C.Y.; Chen P.F.; Setzer D.; Tanimura M.; Li W.H.; Gotto A.M.; Chan L.; The complete cDNA and amino acid sequence of human apolipoprotein B-100. J Biol Chem 1986,261(28),12918-12921","journal-title":"J Biol Chem"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1006\/geno.1997.4898","volume":"45","author":"Myant N.B.","year":"1997","unstructured":"Myant N.B.; Forbes S.A.; Day I.N.; Gallagher J.; Estimation of the age of the ancestral arginine3500-->glutamine mutation in human apoB-100. Genomics 1997,45(1),78-87","journal-title":"Genomics"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1373\/clinchem.2009.129759","volume":"55","author":"Humphries S.E.","year":"2009","unstructured":"Humphries S.E.; Neely R.D.; Whittall R.A.; Troutt J.S.; Konrad R.J.; Scartezini M.; Li K.W.; Cooper J.A.; Acharya J.; Neil A.; Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9. Clin Chem 2009,55(12),2153-2161","journal-title":"Clin Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"Abifadel M.","year":"2003","unstructured":"Abifadel M.; Varret M.; Rab&#xE8;s J-P.; Allard D.; Ouguerram K.; Devillers M.; Cruaud C.; Benjannet S.; Wickham L.; Erlich D.; Derr&#xE9; A.; Vill&#xE9;ger L.; Farnier M.; Beucler I.; Bruckert E.; Chambaz J.; Chanu B.; Lecerf J-M.; Luc G.; Moulin P.; Weissenbach J.; Prat A.; Krempf M.; Junien C.; Seidah N.G.; Boileau C.; Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003,34(2),154-156","journal-title":"Nat Genet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCGENETICS.115.001129","volume":"8","author":"Hopkins P.N.","year":"2015","unstructured":"Hopkins P.N.; Defesche J.; Fouchier S.W.; Bruckert E.; Luc G.; Cariou B.; Sjouke B.; Leren T.P.; Harada-Shiba M.; Mabuchi H.; Rab&#xE8;s J-P.; Carri&#xE9; A.; van Heyningen C.; Carreau V.; Farnier M.; Teoh Y.P.; Bourbon M.; Kawashiri M-A.; Nohara A.; Soran H.; Marais A.D.; Tada H.; Abifadel M.; Boileau C.; Chanu B.; Katsuda S.; Kishimoto I.; Lambert G.; Makino H.; Miyamoto Y.; Pichelin M.; Yagi K.; Yamagishi M.; Zair Y.; Mellis S.; Yancopoulos G.D.; Stahl N.; Mendoza J.; Du Y.; Hamon S.; Krempf M.; Swergold G.D.; Characterization of autosomal dominant hypercholesterolemia caused by PCSK9 gain of mutations and its specific treatment with alirocumab, aPCSK9 monoclonal antibody. Circ Cardiovasc Genet 2015,8(6),823-831","journal-title":"Circ Cardiovasc Genet"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2013.09.007","volume":"231","author":"Awan Z.","year":"2013","unstructured":"Awan Z.; Choi H.Y.; Stitziel N.; Ruel I.; Bamimore M.A.; Husa R.; Gagnon M-H.; Wang R-H.L.; Peloso G.M.; Hegele R.A.; Seidah N.G.; Kathiresan S.; Genest J.; APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis 2013,231(2),218-222","journal-title":"Atherosclerosis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.gene.2014.09.020","volume":"555","author":"Fellin R.","year":"2015","unstructured":"Fellin R.; Arca M.; Zuliani G.; Calandra S.; Bertolini S.; The history of Autosomal Recessive Hypercholesterolemia (ARH). From clinical observations to gene identification. Gene 2015,555(1),23-32","journal-title":"Gene"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MOL.0b013e328361f6c6","volume":"24","author":"Fouchier S.W.","year":"2013","unstructured":"Fouchier S.W.; Defesche J.C.; Lysosomal acid lipase A and the hypercholesterolaemic phenotype. Curr Opin Lipidol 2013,24(4),332-338","journal-title":"Curr Opin Lipidol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/MOL.0000000000000071","volume":"25","author":"Patel S.B.","year":"2014","unstructured":"Patel S.B.; Recent advances in understanding the STSL locus and ABCG5\/ABCG8 biology. Curr Opin Lipidol 2014,25(3),169-175","journal-title":"Curr Opin Lipidol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(00)03587-X","volume":"357","author":"Umans-Eckenhausen M.A.","year":"2001","unstructured":"Umans-Eckenhausen M.A.; Defesche J.C.; Sijbrands E.J.; Scheerder R.L.; Kastelein J.J.; Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet 2001,357(9251),165-168","journal-title":"Lancet"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","volume":"5","author":"Goldberg A.C.","year":"2011","unstructured":"Goldberg A.C.; Hopkins P.N.; Toth P.P.; Ballantyne C.M.; Rader D.J.; Robinson J.G.; Daniels S.R.; Gidding S.S.; de Ferranti S.D.; Ito M.K.; McGowan M.P.; Moriarty P.M.; Cromwell W.C.; Ross J.L.; Ziajka P.E.; Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol National Lipid Association Expert Panel on Familial Hypercholesterolemia2011,5(3)(Suppl.),133-140","journal-title":"J Clin Lipidol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"a1095","DOI":"10.1136\/bmj.a1095","volume":"337","author":"Wierzbicki A.S.","year":"2008","unstructured":"Wierzbicki A.S.; Humphries S.E.; Minhas R.; Familial hypercholesterolaemia: summary of NICE guidance. BMJ Guideline Development Group2008,337,a1095","journal-title":"BMJ"},{"key":"ref=58","year":"2020","unstructured":"Familial hypercholesterolaemia-Report of a second WHO consultation, Geneva. 2020 https:\/\/apps.who.int\/iris\/handle\/10665\/66346"},{"key":"ref=59","year":"2020","unstructured":"Identification and management of familial hypercholesterolaemia (FH). 2020 https:\/\/www.nice.org.uk\/guidance\/cg71\/update\/CG71\/documents\/familial-"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2015.03.003","volume":"240","author":"Haralambos K.","year":"2015","unstructured":"Haralambos K.; Whatley S.D.; Edwards R.; Gingell R.; Townsend D.; Ashfield-Watt P.; Lansberg P.; Datta D.B.N.; McDowell I.F.W.; Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis 2015,240(1),190-196","journal-title":"Atherosclerosis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","volume":"36","author":"Wiegman A.","year":"2015","unstructured":"Wiegman A.; Gidding S.S.; Watts G.F.; Chapman M.J.; Ginsberg H.N.; Cuchel M.; Ose L.; Averna M.; Boileau C.; Bor&#xE9;n J.; Bruckert E.; Catapano A.L.; Defesche J.C.; Descamps O.S.; Hegele R.A.; Hovingh G.K.; Humphries S.E.; Kovanen P.T.; Kuivenhoven J.A.; Masana L.; Nordestgaard B.G.; Pajukanta P.; Parhofer K.G.; Raal F.J.; Ray K.K.; Santos R.D.; Stalenhoef A.F.H.; Steinhagen-Thiessen E.; Stroes E.S.; Taskinen M.R.; Tybj&#xE6;rg-Hansen A.; Wiklund O.; Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J European Atherosclerosis Society Consensus Panel2015,36(36),2425-2437","journal-title":"Eur Heart J"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2016.09.061","volume":"254","author":"Martin R.","year":"2016","unstructured":"Martin R.; Latten M.; Hart P.; Murray H.; Bailie D.A.; Crockard M.; Lamont J.; Fitzgerald P.; Graham C.A.; Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations. Atherosclerosis 2016,254,8-13","journal-title":"Atherosclerosis"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/MOL.0000000000000430","volume":"28","author":"Graham C.A.","year":"2017","unstructured":"Graham C.A.; Latten M.J.; Hart P.J.; Molecular diagnosis of familial hypercholesterolaemia. Curr Opin Lipidol 2017,28(4),313-320","journal-title":"Curr Opin Lipidol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/joim.12263","volume":"276","author":"Maglio C.","year":"2014","unstructured":"Maglio C.; Mancina R.M.; Motta B.M.; Stef M.; Pirazzi C.; Palacios L.; Askaryar N.; Bor&#xE9;n J.; Wiklund O.; Romeo S.; Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing. J Intern Med 2014,276(4),396-403","journal-title":"J Intern Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrg3493","volume":"14","author":"Katsanis S.H.","year":"2013","unstructured":"Katsanis S.H.; Katsanis N.; Molecular genetic testing and the future of clinical genomics. Nat Rev Genet 2013,14(6),415-426","journal-title":"Nat Rev Genet"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-genom-083115-022348","volume":"17","author":"Strande N.T.","year":"2016","unstructured":"Strande N.T.; Berg J.S.; Defining the clinical value of a genomic diagnosis in the era of next-generation sequencing. Annu Rev Genomics Hum Genet 2016,17,303-332","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1586\/14737159.2015.976555","volume":"15","author":"de Koning T.J.","year":"2015","unstructured":"de Koning T.J.; Jongbloed J.D.; Sikkema-Raddatz B.; Sinke R.J.; Targeted next-generation sequencing panels for monogenetic disorders in clinical diagnostics: the opportunities and challenges. Expert Rev Mol Diagn 2015,15(1),61-70","journal-title":"Expert Rev Mol Diagn"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.canlet.2012.11.025","volume":"340","author":"Xuan J.","year":"2013","unstructured":"Xuan J.; Yu Y.; Qing T.; Guo L.; Shi L.; Next-generation sequencing in the clinic: promises and challenges. Cancer Lett 2013,340(2),284-295","journal-title":"Cancer Lett"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/ng.712","volume":"42","author":"Vissers L.E.","year":"2010","unstructured":"Vissers L.E.; de Ligt J.; Gilissen C.; Janssen I.; Steehouwer M.; de Vries P.; van Lier B.; Arts P.; Wieskamp N.; del Rosario M.; van Bon B.W.; Hoischen A.; de Vries B.B.; Brunner H.G.; Veltman J.A.; A de novo paradigm for mental retardation. Nat Genet 2010,42(12),1109-1112","journal-title":"Nat Genet"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/ejhg.2011.258","volume":"20","author":"Gilissen C.","year":"2012","unstructured":"Gilissen C.; Hoischen A.; Brunner H.G.; Veltman J.A.; Disease gene identification strategies for exome sequencing. Eur J Hum Genet 2012,20(5),490-497","journal-title":"Eur J Hum Genet"},{"key":"ref=71","unstructured":"Sure Select Target enrichment system. For Illumina multiplexed sequencing platforms. Protocol. Agilent Technologies. https:\/\/www.genomics.agilent.com\/article.jsp?pageId=3083"},{"key":"ref=72","year":"2020","unstructured":"Illumina products. TruSight one sequencing panels. 2020 https:\/\/www.illumina.com\/products\/by-type\/clinical-research-products\/trusight-one.html"},{"key":"ref=73","unstructured":"Illumina. Cancer genomics research. Targeting known variants for cancer related genes. https:\/\/www.illumina.com\/areas-of-interest\/cancer\/research\/sequencing-methods\/targeted-cancer-seq.html"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/humu.22332","volume":"34","author":"Sikkema-Raddatz B.","year":"2013","unstructured":"Sikkema-Raddatz B.; Johansson L.F.; de Boer E.N.; Almomani R.; Boven L.G.; van den Berg M.P.; van Spaendonck-Zwarts K.Y.; van Tintelen J.P.; Sijmons R.H.; Jongbloed J.D.; Sinke R.J.; Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat 2013,34(7),1035-1042","journal-title":"Hum Mutat"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12881-015-0230-x","volume":"16","author":"Radovica-Spalvina I.","year":"2015","unstructured":"Radovica-Spalvina I.; Latkovskis G.; Silamikelis I.; Fridmanis D.; Elbere I.; Ventins K.; Ozola G.; Erglis A.; Klovins J.; Next-generation-sequencing-based identification of familial hypercholesterolemia-related mutations in subjects with increased LDL-C levels in a latvian population. BMC Med Genet 2015,16,86","journal-title":"BMC Med Genet"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2350-15-70","volume":"15","author":"Norsworthy P.J.","year":"2014","unstructured":"Norsworthy P.J.; Vandrovcova J.; Thomas E.R.A.; Campbell A.; Kerr Soutar A.K.; Smith B.H.; Dominiczak A.F.; Porteous D.J.; Morris A.D.; Generation Scotland; Aitman; T.J. Targeted genetic testing for familial hypercholesterolemia using next generation sequencing: a population-based study. BMC Med Genet 2014,15,70","journal-title":"BMC Med Genet"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosissup.2017.07.002","volume":"29","author":"Pirillo A.","year":"2017","unstructured":"Pirillo A.; Garlaschelli K.; Arca M.; Averna M.; Bertolini S.; Calandra S.; Tarugi P.; Catapano A.L.; Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atheroscler Suppl LIPIGEN Group2017,29,17-24","journal-title":"Atheroscler Suppl"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/jmedgenet-2014-102405","volume":"51","author":"Futema M.","year":"2014","unstructured":"Futema M.; Plagnol V.; Li K.; Whittall R.A.; Neil H.A.W.; Seed M.; Whole exome secuencing of familial hypercholesterolemia patients negative for LDLR\/APOB\/PCSK9 mutations. J Med Genet Simon Broome Consortium2014,51(8),537-544","journal-title":"J Med Genet"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.gene.2015.03.064","volume":"565","author":"Al-Allaf F.A.","year":"2015","unstructured":"Al-Allaf F.A.; Athar M.; Abduljaleel Z.; Taher M.M.; Khan W.; Ba-Hammam F.A.; Abalkhail H.; Alashwal A.; Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease. Gene 2015,565(1),76-84","journal-title":"Gene"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/ejhg.2015.100","volume":"24","author":"Br&#xE6;nne I.","year":"2016","unstructured":"Br&#xE6;nne I.; Kleinecke M.; Reiz B.; Graf E.; Strom T.; Wieland T.; Fischer M.; Kessler T.; Hengstenberg C.; Meitinger T.; Erdmann J.; Schunkert H.; Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur J Hum Genet 2016,24(2),191-197","journal-title":"Eur J Hum Genet"},{"key":"ref=81","year":"2014","unstructured":"The World Factbook Central Intelligence Agency2014 https:\/\/www.cia.gov\/library\/publications\/download\/download-2014\/index.html","journal-title":"The World Factbook"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","volume":"9","author":"DeGoma E.M.","year":"2016","unstructured":"DeGoma E.M.; Ahmad Z.S.; O\u2019Bien E.C.; Kindt I.; Shrader P.; Newman C.B.; Pokharel Y.; Baum S.J.; Hemphill L.C.; Hudgins L.C.; Ahmed C.D.; Gidding S.S.; Duffy D.; Neal W.; Wilemon K.; Roe M.T.; Rader D.J.; Ballantyne C.M.; Linton M.F.; Duell P.; Shapiro M.D.; Moriarty P.M.; Knowles J.W.; Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-familial hypercholesterolemia registry. Circ Cardiovasc Genet 2016,9(3),240-249","journal-title":"Circ Cardiovasc Genet"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.jacl.2011.03.453","volume":"5","author":"Daniels S.R.","year":"2011","unstructured":"Daniels S.R.; Gidding S.S.; de Ferranti S.D.; Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011,5(3)(Suppl.),S30-S37","journal-title":"J Clin Lipidol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jama.292.3.331","volume":"292","author":"Wiegman A.","year":"2004","unstructured":"Wiegman A.; Hutten B.A.; de Groot E.; Rodenburg J.; Bakker H.D.; B&#xFC;ller H.R.; Sijbrands E.J.; Kastelein J.J.; Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004,292(3),331-337","journal-title":"JAMA"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.atherosclerosis.2014.05.917","volume":"235","author":"Narverud I.","year":"2014","unstructured":"Narverud I.; Retterst&#xF8;l K.; Iversen P.O.; Halvorsen B.; Ueland T.; Ulven S.M.; Ose L.; Aukrust P.; Veier&#xF8;d M.B.; Holven K.B.; Markers of atherosclerotic development in children with familial hypercholesterolemia: a literature review. Atherosclerosis 2014,235(2),299-309","journal-title":"Atherosclerosis"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1136\/archdischild-2011-300081","volume":"97","author":"Kusters D.M.","year":"2012","unstructured":"Kusters D.M.; de Beaufort C.; Widhalm K.; Guardamagna O.; Bratina N.; Ose L.; Wiegman A.; Paediatric screening for hypercholesterolaemia in Europe. Arch Dis Child 2012,97(3),272-276","journal-title":"Arch Dis Child"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1161\/CIRCULATIONAHA.107.717033","volume":"117","author":"McGill H.C.","year":"2008","unstructured":"McGill H.C.; McMahan C.A.; Gidding S.S.; Preventing heart disease in the 21st century: implications of the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study. Circulation 2008,117(9),1216-1227","journal-title":"Circulation"},{"key":"ref=88","year":"1968","unstructured":"Principles and Practice of screening for disease Public Health Papers 341968 https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/37650\/WHO_PHP_34.pdf?sequence=17","journal-title":"Principles and Practice of screening for disease"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/clc.22050","volume":"35","author":"Kwiterovich P.O.","year":"2012","unstructured":"Kwiterovich P.O.; Gidding S.S.; Universal screening of cholesterol in children. Clin Cardiol 2012,35(11),662-664","journal-title":"Clin Cardiol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1136\/bmj.39300.616076.55","volume":"335","author":"Wald D.S.","year":"2007","unstructured":"Wald D.S.; Bestwick J.P.; Wald N.J.; Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ 2007,335(7620),599","journal-title":"BMJ"},{"key":"ref=91","first-page":"26","volume":"11","author":"Leren T.P.","year":"2008","unstructured":"Leren T.P.; Finborud T.H.; Manshaus T.E.; Ose L.; Berge K.E.; Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet 2008,11(1),26-35","journal-title":"Community Genet"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/MOL.0b013e32833c14e2","volume":"21","author":"Datta B.N.","year":"2010","unstructured":"Datta B.N.; McDowell I.F.; Rees A.; Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol 2010,21(4),366-371","journal-title":"Curr Opin Lipidol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.cjca.2014.09.028","volume":"30","author":"Genest J.","year":"2014","unstructured":"Genest J.; Hegele R.A.; Bergeron J.; Brophy J.; Carpentier A.; Couture P.; Davignon J.; Dufour R.; Frohlich J.; Gaudet D.; Gupta M.; Krisnamoorthy P.; Mancini J.; McCrindle B.; Raggi P.; Ruel I.; St-Pierre J.; Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol 2014,30(12),1471-1481","journal-title":"Can J Cardiol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2471\/BLT.07.050112","volume":"86","author":"Andermann A.","year":"2008","unstructured":"Andermann A.; Blancquaert I.; Beauchamp S.; D&#xE9;ry V.; Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008,86(4),317-319","journal-title":"Bull World Health Organ"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.atherosclerosissup.2017.05.019","volume":"30","author":"Louter L.","year":"2017","unstructured":"Louter L.; Defesche J.; Roeters van Lennep J.; Cascade screening for familial hypercholesterolemia: Practical consequences. Atheroscler Suppl 2017,30,77-85","journal-title":"Atheroscler Suppl"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jacl.2014.05.008","volume":"8","author":"Ademi Z.","year":"2014","unstructured":"Ademi Z.; Watts G.F.; Pang J.; Sijbrands E.J.E.; van Bockxmeer F.M.; O\u2019Leary P.; Geelhoed E.; Liew D.; Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. J Clin Lipidol 2014,8(4),390-400","journal-title":"J Clin Lipidol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ijcard.2014.12.070","volume":"181","author":"Chen C.X.","year":"2015","unstructured":"Chen C.X.; Hay J.W.; Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. Int J Cardiol 2015,181,417-424","journal-title":"Int J Cardiol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/VHRM.S192401","volume":"16","author":"Alonso R.","year":"2020","unstructured":"Alonso R.; Perez de Isla L.; Mu&#xF1;iz-Grijalvo O.; Mata P.; Barriers to early diagnosis and treatment of familial hypercholesterolemia: current perspectives on improving patient care. Vasc Health Risk Manag 2020,16,11-25","journal-title":"Vasc Health Risk Manag"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.001","volume":"22","author":"Vallejo-Vaz A.J.","year":"2016","unstructured":"Vallejo-Vaz A.J.; Akram A.; Kondapally Seshasai S.R.; Cole D.; Watts G.F.; Hovingh G.K.; Kastelein J.J.; Mata P.; Raal F.J.; Santos R.D.; Soran H.; Freiberger T.; Abifadel M.; Aguilar-Salinas C.A.; Alnouri F.; Alonso R.; Al-Rasadi K.; Banach M.; Bogsrud M.P.; Bourbon M.; Bruckert E.; Car J.; Ceska R.; Corral P.; Descamps O.; Dieplinger H.; Do C.T.; Durst R.; Ezhov M.V.; Fras Z.; Gaita D.; Gaspar I.M.; Genest J.; Harada-Shiba M.; Jiang L.; Kayikcioglu M.; Lam C.S.; Latkovskis G.; Laufs U.; Liberopoulos E.; Lin J.; Lin N.; Maher V.; Majano N.; Marais A.D.; M&#xE4;rz W.; Mirrakhimov E.; Miserez A.R.; Mitchenko O.; Nawawi H.; Nilsson L.; Nordestgaard B.G.; Paragh G.; Petrulioniene Z.; Pojskic B.; Reiner &#x17D;.; Sahebkar A.; Santos L.E.; Schunkert H.; Shehab A.; Slimane M.N.; Stoll M.; Su T.C.; Susekov A.; Tilney M.; Tomlinson B.; Tselepis A.D.; Vohnout B.; Wid&#xE9;n E.; Yamashita S.; Catapano A.L.; Ray K.K.; Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler Suppl 2016,22,1-32","journal-title":"Atheroscler Suppl"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"Khera A.V.","year":"2016","unstructured":"Khera A.V.; Won H.H.; Peloso G.M.; Lawson K.S.; Bartz T.M.; Deng X.; van Leeuwen E.M.; Natarajan P.; Emdin C.A.; Bick A.G.; Morrison A.C.; Brody J.A.; Gupta N.; Nomura A.; Kessler T.; Duga S.; Bis J.C.; van Duijn C.M.; Cupples L.A.; Psaty B.; Rader D.J.; Danesh J.; Schunkert H.; McPherson R.; Farrall M.; Watkins H.; Lander E.; Wilson J.G.; Correa A.; Boerwinkle E.; Merlini P.A.; Ardissino D.; Saleheen D.; Gabriel S.; Kathiresan S.; Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J Am Coll Cardiol 2016,67(22),2578-2589","journal-title":"J Am Coll Cardiol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s40265-015-0466-y","volume":"75","author":"Ito M.K.","year":"2015","unstructured":"Ito M.K.; Watts G.F.; Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia. Drugs 2015,75(15),1715-1724","journal-title":"Drugs"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","volume":"105","author":"Gagn&#xE9; C.","year":"2002","unstructured":"Gagn&#xE9; C.; Gaudet D.; Bruckert E.; Efficacy and safety of ezetimibeco administered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002,105(21),2469-24","journal-title":"Circulation"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nature04399","volume":"438","author":"Maxfield F.R.","year":"2005","unstructured":"Maxfield F.R.; Tabas I.; Role of cholesterol and lipid organization in disease. Nature 2005,438(7068),612-621","journal-title":"Nature"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev.pharmtox.48.113006.094746","volume":"48","author":"Gille A.","year":"2008","unstructured":"Gille A.; Bodor E.T.; Ahmed K.; Offermanns S.; Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008,48,79-106","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.coph.2017.04.005","volume":"33","author":"Chang Y.","year":"2017","unstructured":"Chang Y.; Robidoux J.; Dyslipidemia management update. Curr Opin Pharmacol 2017,33,47-55","journal-title":"Curr Opin Pharmacol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11739-011-0653-0","volume":"8","author":"Scaldaferri F.","year":"2013","unstructured":"Scaldaferri F.; Pizzoferrato M.; Ponziani F.R.; Gasbarrini G.; Gasbarrini A.; Use and indications of cholestyramine and bile acid sequestrants. Intern Emerg Med 2013,8(3),205-210","journal-title":"Intern Emerg Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jacl.2011.01.005","volume":"5","author":"Davidson M.H.A.","year":"2011","unstructured":"Davidson M.H.A.; A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia. J Clin Lipidol 2011,5(2),76-81","journal-title":"J Clin Lipidol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1126\/science.1093131","volume":"303","author":"Altmann S.W.","year":"2004","unstructured":"Altmann S.W.; Davis H.R.; Zhu L.J.; Yao X.; Hoos L.M.; Tetzloff G.; Iyer S.P.; Maguire M.; Golovko A.; Zeng M.; Wang L.; Murgolo N.; Graziano M.P.; Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004,303(5661),1201-1204","journal-title":"Science"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.2174\/138945007782403847","volume":"8","author":"Temel R.E.","year":"2007","unstructured":"Temel R.E.; Rudel L.L.; Diet effects on atherosclerosis in mice. Curr Drug Targets 2007,8(11),1150-1160","journal-title":"Curr Drug Targets"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","volume":"72","author":"Rosenson R.S.","year":"2018","unstructured":"Rosenson R.S.; Hegele R.A.; Fazio S.; Cannon C.P.; The evolving future of PCSK9 inhibitors. J Am Coll Cardiol 2018,72(3),314-329","journal-title":"J Am Coll Cardiol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1016\/j.jacc.2016.09.928","volume":"68","author":"Robinson J.G.","year":"2016","unstructured":"Robinson J.G.; Huijgen R.; Ray K.; Persons J.; Kastelein J.J.; Pencina M.J.; Determining when to add nonstatin therapy. J Am Coll Cardiol 2016,68(22),2412-2421","journal-title":"J Am Coll Cardiol"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2018.06.859","volume":"277","author":"Raal F.J.","year":"2018","unstructured":"Raal F.J.; Hovingh G.K.; Catapano A.L.; Familial hypercholesterolemia treatments: Guidelines and new therapies. Atherosclerosis 2018,277,483-492","journal-title":"Atherosclerosis"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/eurheartj\/eht549","volume":"36","author":"Santos R.D.","year":"2015","unstructured":"Santos R.D.; Duell P.B.; East C.; Guyton J.R.; Moriarty P.M.; Chin W.; Mittleman R.S.; Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 2015,36(9),566-575","journal-title":"Eur Heart J"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/MOL.0b013e3283402f53","volume":"21","author":"Thompson G.R.","year":"2010","unstructured":"Thompson G.R.; Catapano A.; Saheb S.; Atassi-Dumont M.; Barbir M.; Eriksson M.; Paulweber B.; Sijbrands E.; Stalenhoef A.F.; Parhofer K.G.; Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 2010,21(6),492-498","journal-title":"Curr Opin Lipidol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/jcdd5020027","volume":"5","author":"Julius U.","year":"2018","unstructured":"Julius U.; Current role of lipoprotein apheresis in the treatment of high-risk patients. J Cardiovasc Dev Dis 2018,5(2),27","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref=116","author":"Raal F.J.","year":"2019","unstructured":"Raal F.J.; Orion-9 Inclisiran for heterozygous familial hypercholesterolemia. American Heart Association Annual Scientific Sessions (AHA 2019) 2019","journal-title":"American Heart Association Annual Scientific Sessions (AHA 2019)"},{"key":"ref=117","author":"Watts G.F.","year":"2019","unstructured":"Watts G.F.; RNA interference targeting hepatic angiopoietin-like protein 3 results in prolonged reduction in plasma triglycerides and LDL-C in human subjects. American Heart Association Annual Scientific Sessions (AHA 2019) 2019","journal-title":"American Heart Association Annual Scientific Sessions (AHA 2019)"},{"key":"ref=118","unstructured":"A gene therapy study for homozygous Familiar hypercholesterolemia. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02651675"},{"key":"ref=119","unstructured":"Genomics","journal-title":"Tier 1 genomic applications and their importance to public health"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871530321666210208212148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/191236\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871530321666210208212148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T23:37:18Z","timestamp":1724456238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/191236\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530321666210208212148","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-08-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}